1-oxo-1,2,3,4-tetrahydroisoquinoline: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 150896 |
| CHEMBL ID | 1688212 |
| SCHEMBL ID | 67710 |
| SCHEMBL ID | 11267501 |
| MeSH ID | M0157627 |
| Synonym |
|---|
| AC-5218 |
| 1,2,3,4-tetrahydroisoquinolin-1-one |
| EN300-43275 |
| 3,4-dihydro-1(2h)-isoquinolinone |
| F2189-0996 |
| OPREA1_511002 , |
| 3,4-dihydro-2h-isoquinolin-1-one |
| 1196-38-9 |
| AKOS002232785 |
| AKOS003625709 |
| STK926192 |
| CHEMBL1688212 , |
| joz , |
| bdbm50339016 |
| 1-keto-1,2,3,4-tetrahydroisoquinoline |
| 1-oxo-1,2,3,4-tetrahydroisoquinoline |
| 1(2h)-isoquinolinone, 3,4-dihydro- |
| 3,4-dihydroisoquinolin-1(2h)-one |
| FT-0600427 |
| AM20020275 |
| AB07451 |
| SCHEMBL67710 |
| 3NUU |
| YWPMKTWUFVOFPL-UHFFFAOYSA-N |
| 3,4-dihydroisoquinoline-1(2h)-one |
| SCHEMBL11267501 |
| DTXSID40152517 |
| 3,4-dihydroisocarbostyril |
| J-511194 |
| mfcd00853963 |
| CS-W008863 |
| Z56801375 |
| 3,4-dihydro-1-isoquinolinone |
| dihydroisoquinolone |
| Q27461749 |
| SY021304 |
| hydroxy-3,4-dihydroisoquinoline |
| 7R-1504 |
| BCP27476 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | IC50 (µMol) | 169.0000 | 0.0025 | 1.4513 | 9.0000 | AID580957 |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0002 | 0.8123 | 9.8100 | AID1252347 |
| Protein mono-ADP-ribosyltransferase PARP10 | Homo sapiens (human) | IC50 (µMol) | 85.9839 | 0.5623 | 4.1053 | 9.7724 | AID1252345; AID1252346; AID1515545 |
| Protein mono-ADP-ribosyltransferase PARP11 | Homo sapiens (human) | IC50 (µMol) | 7.9716 | 2.1000 | 5.0453 | 8.0000 | AID1515546 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1252345 | Inhibition of PARP-10 L926G mutant (unknown origin) mediated ADP-ribosylation of SRPK2 by fluorescence analysis using 3 uM SRPK2 as a substrate | 2015 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21 | Selective inhibition of PARP10 using a chemical genetics strategy. |
| AID1252346 | Inhibition of PARP-10 (unknown origin) mediated ADP-ribosylation of SRPK2 by fluorescence analysis using 3 uM SRPK2 as a substrate | 2015 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21 | Selective inhibition of PARP10 using a chemical genetics strategy. |
| AID1376993 | Antibacterial activity against Staphylococcus aureus ATCC 29213 at 50 ug/ml after 24 hrs by MTT assay | 2017 | Journal of natural products, 06-23, Volume: 80, Issue:6 | Mollecarbamates, Molleureas, and Molledihydroisoquinolone, o-Carboxyphenethylamide Metabolites of the Ascidian Didemnum molle Collected in Madagascar. |
| AID1376992 | Antibacterial activity against Escherichia coli ATCC 25922 at 50 ug/ml after 24 hrs by MTT assay | 2017 | Journal of natural products, 06-23, Volume: 80, Issue:6 | Mollecarbamates, Molleureas, and Molledihydroisoquinolone, o-Carboxyphenethylamide Metabolites of the Ascidian Didemnum molle Collected in Madagascar. |
| AID1376991 | Antibacterial activity against Pseudomonas aeruginosa ATCC 47085 at 50 ug/ml after 24 hrs by MTT assay | 2017 | Journal of natural products, 06-23, Volume: 80, Issue:6 | Mollecarbamates, Molleureas, and Molledihydroisoquinolone, o-Carboxyphenethylamide Metabolites of the Ascidian Didemnum molle Collected in Madagascar. |
| AID1918421 | Inhibition of human NNMT measured after 20 mins by luminescence based methyltransferase assay | |||
| AID1515546 | Inhibition of full length human His-SUMO-tagged PARP11 expressed in Escherichia coli BL21 assessed as reduction in MARylation of His6-tagged SRPK2 substrate after 60 mins in presence of NAD+ by chemifluorescence assay | 2019 | ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1 | Rational Design of Cell-Active Inhibitors of PARP10. |
| AID580957 | Inhibition of His-tagged-truncated human PDK1 preincubated with substrate biotinylated-AKT3 for 30 mins measured after 3 hrs by Scintillation proximity assay | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8 | Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery. |
| AID1515545 | Inhibition of human PARP10 catalytic domain assessed as reduction in MARylation of His6-tagged SRPK2 substrate after 60 mins in presence of NAD+ by chemifluorescence assay | 2019 | ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1 | Rational Design of Cell-Active Inhibitors of PARP10. |
| AID1252347 | Inhibition of PARP1 (unknown origin) by fluorescence analysis | 2015 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21 | Selective inhibition of PARP10 using a chemical genetics strategy. |
| AID1515547 | Selectivity ratio of IC50 for full length human His-SUMO-tagged PARP11 expressed in Escherichia coli BL21 to IC50 for human PARP10 catalytic domain | 2019 | ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1 | Rational Design of Cell-Active Inhibitors of PARP10. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.92) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||